Jan Andrzej Walewski
Impact in
- Pathology and Forensic Medicine top 0.02%
- Lymphoma Diagnosis and Treatment
- Genetics top 0.1%
- Chronic Lymphocytic Leukemia Research
Papers in
-
- Lymphoma Diagnosis and Treatment 194
- Genetics 83
- Chronic Lymphocytic Leukemia Research 80
- Co-authors
- Ruth Pettengell (9 shared papers)Marco Ladetto (6 shared papers)Michael G. Pfreundschuh (10 shared papers)ANDREW S. JACK (6 shared papers)Matti Aapro (3 shared papers)Christoph Carl Zielinski (2 shared papers)Damien Charles Weber (2 shared papers)Nora Kearney (2 shared papers)
- Journals
- Blood (64 papers)Annals of Oncology (21 papers)Medical Oncology (13 papers)British Journal of Haematology (10 papers)The Lancet Oncology (8 papers)
- Partner nations
- PolandUnited StatesGermany
In The Last Decade
Jan Andrzej Walewski
259 papers receiving 16.3k citations
Jan Andrzej Walewski's Hit Papers
Peers
Comparison fields: 5 of 152
- Pathology and Forensic Medicine 10.5k
- Genetics 3.7k
- Oncology 7.9k
- Neurology 2.6k
- Dermatology 1.2k
Countries citing papers authored by Jan Andrzej Walewski
This map shows the geographic impact of Jan Andrzej Walewski's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jan Andrzej Walewski with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jan Andrzej Walewski more than expected).
Fields of papers citing papers by Jan Andrzej Walewski
This network shows the impact of papers produced by Jan Andrzej Walewski. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jan Andrzej Walewski. The network helps show where Jan Andrzej Walewski may publish in the future.
Co-authors
The 25 scholars most cited alongside Jan Andrzej Walewski, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 271 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group Hit paper breakdown → | 2006 | 1705 |
| 2 | Bortezomib plus rituximab alone in patients with relapsed, rituximab-naive or rituximab-sensitive, follicular lymphoma: a randomised phase 3 Trial. Hit paper breakdown → | 2011 | 1133 |
| 3 | 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours Hit paper breakdown → | 2010 | 863 |
| 4 | Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up Hit paper breakdown → | 2015 | 711 |
| 5 | CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group Hit paper breakdown → | 2011 | 653 |
| 6 | Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin’s Lymphoma Hit paper breakdown → | 2017 | 593 |
| 7 | Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial Hit paper breakdown → | 2015 | 573 |
| 8 | Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial Hit paper breakdown → | 2018 | 554 |
| 9 | Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up Hit paper breakdown → | 2017 | 502 |
| 10 | Belinostat in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma: Results of the Pivotal Phase II BELIEF (CLN-19) Study Hit paper breakdown → | 2015 | 466 |
| 11 | Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial Hit paper breakdown → | 2017 | 450 |
| 12 | 2006 | 408 | |
| 13 | Treatment of Older Patients with Mantle-Cell Lymphoma Hit paper breakdown → | 2012 | 402 |
| 14 | 2007 | 322 | |
| 15 | 2007 | 320 | |
| 16 | Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger): a randomised, open-label, phase 3 trial of the European Mantle Cell Lymphoma Network Hit paper breakdown → | 2016 | 313 |
| 17 | 2014 | 300 | |
| 18 | 2002 | 258 | |
| 19 | 2009 | 223 | |
| 20 | 2008 | 222 |
About Jan Andrzej Walewski
Jan Andrzej Walewski is a scholar working on Pathology and Forensic Medicine, Genetics, Oncology, Neurology and Hematology, having authored 271 papers that have together received 16.8k indexed citations. Recurring topics across this work include Lymphoma Diagnosis and Treatment (194 papers), Chronic Lymphocytic Leukemia Research (80 papers), Viral-associated cancers and disorders (44 papers), CNS Lymphoma Diagnosis and Treatment (34 papers), Lung Cancer Treatments and Mutations (25 papers), CAR-T cell therapy research (20 papers), Multiple Myeloma Research and Treatments (20 papers) and Acute Lymphoblastic Leukemia research (16 papers). The work is most often cited by research in Pathology and Forensic Medicine (10.5k citations), Genetics (3.7k citations), Oncology (7.9k citations), Neurology (2.6k citations) and Dermatology (1.2k citations). Jan Andrzej Walewski has collaborated with scholars based in Poland, United States and Germany. Frequent co-authors include Ruth Pettengell, Marco Ladetto, Michael G. Pfreundschuh, ANDREW S. JACK, Matti Aapro, Christoph Carl Zielinski, Damien Charles Weber, Nora Kearney, Julia Bohlius and David Cameron. Their work appears in journals such as Blood, Annals of Oncology, Medical Oncology, British Journal of Haematology and The Lancet Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.